- Reduced cash burn per quarter by 20% from $2.5 million to $2 million
- Expect to expand external collaborations in the coming months in IO and ACT
- Publication in Molecular Therapy on self-delivering RNAi targeting PD-1 in ACT for the treatment of malignant melanoma
PR Newswire
MARLBOROUGH, Mass., May 10, 2018